Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
7.79%
EBIT Growth (5y)
56.94%
EBIT to Interest (avg)
0.66
Debt to EBITDA (avg)
5.22
Net Debt to Equity (avg)
0.53
Sales to Capital Employed (avg)
0.64
Tax Ratio
85.13%
Dividend Payout Ratio
20.35%
Pledged Shares
0
Institutional Holding
45.79%
ROCE (avg)
2.41%
ROE (avg)
0.58%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
34
Price to Book Value
2.67
EV to EBIT
288.45
EV to EBITDA
28.29
EV to Capital Employed
2.09
EV to Sales
2.94
PEG Ratio
NA
Dividend Yield
0.06%
ROCE (Latest)
0.72%
ROE (Latest)
-1.59%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend6What is working for the Company
PBT LESS OI(Q)
At Rs 172.71 cr has Grown at 611.1% (vs previous 4Q average
OPERATING PROFIT TO INTEREST(Q)
Highest at 5.55 times
NET SALES(Q)
At Rs 2,751.77 cr has Grown at 24.1% (vs previous 4Q average
-5What is not working for the Company
ROCE(HY)
Lowest at 2.61%
DEBT-EQUITY RATIO(HY)
Highest at 0.70 times
Loading Valuation Snapshot...
Here's what is working for Piramal Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 172.71 cr has Grown at 611.1% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs -33.79 CrMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Operating Profit to Interest - Quarterly
Highest at 5.55 times
in the last five quartersMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Net Sales - Quarterly
At Rs 2,751.77 cr has Grown at 24.1% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 2,217.84 CrMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Here's what is not working for Piramal Pharma
Debt-Equity Ratio - Half Yearly
Highest at 0.70 times
in the last five half yearly periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
